236 related articles for article (PubMed ID: 31967940)
21. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
[TBL] [Abstract][Full Text] [Related]
22. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
23. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
[TBL] [Abstract][Full Text] [Related]
24. LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer.
Gan S; Qu F; Zhang X; Pan X; Xu D; Cui X; Hou J
Exp Cell Res; 2024 Jan; 434(1):113857. PubMed ID: 38008278
[TBL] [Abstract][Full Text] [Related]
25. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
[TBL] [Abstract][Full Text] [Related]
26. Loss of Speckle-Type POZ Protein Promotes Prostate Cancer Cell Migration and Invasion Through Upregulation of MCP-1.
Shi J; Cao J; Lu X; Fan L; Guo H; Fu J
Med Sci Monit; 2021 Apr; 27():e929199. PubMed ID: 33872295
[TBL] [Abstract][Full Text] [Related]
27. Untangling trapped topoisomerases with tyrosyl-DNA phosphodiesterases.
Zagnoli-Vieira G; Caldecott KW
DNA Repair (Amst); 2020 Oct; 94():102900. PubMed ID: 32653827
[TBL] [Abstract][Full Text] [Related]
28. The emerging role of speckle-type POZ protein (SPOP) in cancer development.
Mani RS
Drug Discov Today; 2014 Sep; 19(9):1498-502. PubMed ID: 25058385
[TBL] [Abstract][Full Text] [Related]
29. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
[TBL] [Abstract][Full Text] [Related]
30. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
[TBL] [Abstract][Full Text] [Related]
31. TDP2 suppresses chromosomal translocations induced by DNA topoisomerase II during gene transcription.
Gómez-Herreros F; Zagnoli-Vieira G; Ntai I; Martínez-Macías MI; Anderson RM; Herrero-Ruíz A; Caldecott KW
Nat Commun; 2017 Aug; 8(1):233. PubMed ID: 28794467
[TBL] [Abstract][Full Text] [Related]
32. Deregulation of SPOP in Cancer.
Zhang H; Jin X; Huang H
Cancer Res; 2023 Feb; 83(4):489-499. PubMed ID: 36512624
[TBL] [Abstract][Full Text] [Related]
33. SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
Bernasocchi T; Theurillat JP
Cancer Lett; 2022 Mar; 529():11-18. PubMed ID: 34974131
[TBL] [Abstract][Full Text] [Related]
34. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Shoag J; Liu D; Blattner M; Sboner A; Park K; Deonarine L; Robinson BD; Mosquera JM; Chen Y; Rubin MA; Barbieri CE
J Clin Invest; 2018 Jan; 128(1):381-386. PubMed ID: 29202479
[TBL] [Abstract][Full Text] [Related]
35. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers.
Kim MS; Je EM; Oh JE; Yoo NJ; Lee SH
APMIS; 2013 Jul; 121(7):626-33. PubMed ID: 23216165
[TBL] [Abstract][Full Text] [Related]
36. Tyrosyl-DNA-phosphodiesterase I (TDP1) participates in the removal and repair of stabilized-Top2α cleavage complexes in human cells.
Borda MA; Palmitelli M; Verón G; González-Cid M; de Campos Nebel M
Mutat Res; 2015 Nov; 781():37-48. PubMed ID: 26421495
[TBL] [Abstract][Full Text] [Related]
37. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
[TBL] [Abstract][Full Text] [Related]
38. Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study.
Bidot S; Yin J; Zhou P; Zhang L; Deeb KK; Smith G; Hill CE; Xiu J; Bilen MA; Case KB; Tinsley M; Carthon B; Harik LR
Arch Pathol Lab Med; 2024 Mar; 148(3):310-317. PubMed ID: 37327205
[TBL] [Abstract][Full Text] [Related]
39. SPOP promotes transcriptional expression of DNA repair and replication factors to prevent replication stress and genomic instability.
Hjorth-Jensen K; Maya-Mendoza A; Dalgaard N; Sigurðsson JO; Bartek J; Iglesias-Gato D; Olsen JV; Flores-Morales A
Nucleic Acids Res; 2018 Oct; 46(18):9484-9495. PubMed ID: 30124983
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression.
Schaefer-Klein JL; Murphy SJ; Johnson SH; Vasmatzis G; Kovtun IV
PLoS One; 2015; 10(11):e0142327. PubMed ID: 26560244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
